TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01644487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: self-expanding nitinol stent
Description: A group of patients who will undergo subsequent primary stenting following successful conventional balloon angioplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon angioplasty
Description: A group of patients who will undergo routine conventional balloon angioplasty alone without stenting
Study: NCT04176367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicergoline from Italy
Description: This is the reference arm of Italy originator Nicergoline.
Study: NCT01712815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine F 18-clevudine
Description: Undergo fluorine F 18-clevudine PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography/computed tomography
Description: Undergo fluorine F18-clevudine PET/CT scan
Study: NCT00510315

Intervention type: OTHER
Intervention: Questionnaires, Laboratory tests, Abdominal MRI
Description: Height, weight, waist and hip circumference; systolic and diastolic blood pressure; questionnaires; fasting blood tests: insulin, glucose, lipids (low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides, LDL pattern, HDL and LDL subspecies), cardiac inflammatory markers (hsCRP, IL-1B, IL-6, IL-10, TNFa), leptin, adiponectin, IGF-1, and IGFBP3; abdominal MRI for visceral and subcutaneous fat measurement

Intervention type: OTHER
Intervention: Questionnaires, Laboratory tests, Abdominal MRI
Description: Height, weight, waist and hip circumference; systolic and diastolic blood pressure; questionnaires; fasting blood tests: insulin, glucose, lipids (low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides, LDL pattern, HDL and LDL subspecies), cardiac inflammatory markers (hsCRP, IL-1B, IL-6, IL-10, TNFa), leptin, adiponectin, IGF-1, and IGFBP3; abdominal MRI for visceral and subcutaneous fat measurement
Study: NCT02765672

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Driving Behavior Interview
Description: This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Driving Behavior Interview
Description: This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Driving Assessment
Description: Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Mini-Mental State Examination (MMSE) and Strength tests. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
Study: NCT01891968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2 subcutaneously on days 1, 4, 8 and 11 of a 21 day cycle.
Study: NCT03829410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Onvansertib orally.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI intravenously.
Study: NCT00968448

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle training
Description: Daily training with a handheld device (Pressure threshold loading). 1x50 breaths with adjustments (gradually increasing levels).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham training
Description: Sham training with same handheld device. 50 breaths daily on the lowest level
Study: NCT01069341

Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab
Description: Intravitreally administered 0.5mg ranibizumab, 3 doses administered monthly.
Study: NCT00922207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir
Description: From week -4 to week 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: From week -4 to week 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: From week -4 to week 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc weekly, from week 1-48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc weekly, from week 1-48

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc weekly, from week 1-48
Study: NCT02114645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Description: in experimentals groups,on fifth and tenth day after embryo transfer 0,5mg leuprolide acetate is given subcutaneously as luteal phase support

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Description: in experimentals groups,on fifth and tenth day after embryo transfer 0,5mg leuprolide acetate is given subcutaneously as luteal phase support

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal progesterone
Description: crinone gel is applied till fetal heart beat is detected

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaginal progesterone
Description: crinone gel is applied till fetal heart beat is detected
Study: NCT01802632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Starting dose 20 mg, administered once daily. If tolerated subsequent cohorts will test increasing doses of AZD9291, until a maximum tolerated dose or maximum feasible dose is defined
Study: NCT03705299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive CVP vs Standard CVP
Study: NCT03781206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO™ 7
Description: PICO™ system (Smith\&Nephew Healthcare, Hull, UK) is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips.
Study: NCT02418806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy groups

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy groups

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help groups
Study: NCT04580199

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroidectomy
Description: to excise the thyroid gland

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroidectomy
Description: to excise the thyroid gland

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroidectomy
Description: to excise the thyroid gland

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroidectomy
Description: to excise the thyroid gland

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroidectomy
Description: to excise the thyroid gland
Study: NCT01490112

Intervention type: DRUG
Intervention: insulin aspart
Description: Subjects who had a first drug date on NovoRapid® were prescribed to inject insulin aspart using vial, FlexPen, NovoLet or Penfill devices. Injected subcutaneously (s.c., under the skin) immediately before meals for 24 weeks
Study: NCT02570295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swiss Army Physical Fitness Training
Description: 2 x 90 minutes strength training and sport games and 2 x 30 minutes endurance training per week during 18 weeks of basic military training
Study: NCT00484575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: given by infusion via AnaConDa for sedation with target MAAS 2-3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol given intravenously for sedation in control group
Study: NCT02243813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
Study: NCT04241224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atherectomy
Description: Endovascular treatment of peripheral arterial disease
Study: NCT04209049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-0833
Description: A single subcutaneous (s.c., under the skin) dose of 0.6 mg NNC0174-0833.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-0833
Description: A single subcutaneous (s.c., under the skin) dose of 0.6 mg NNC0174-0833.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-0833
Description: A single subcutaneous (s.c., under the skin) dose of 0.6 mg NNC0174-0833.
Study: NCT02765672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Driving Assessment
Description: Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Mini-Mental State Examination (MMSE) and Strength tests. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Propensity for Angry Driving Scale
Description: This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Propensity for Angry Driving Scale
Description: This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Integration Questionnaire
Description: This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Integration Questionnaire
Description: This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
Study: NCT04209049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-0833
Description: A single subcutaneous (s.c., under the skin) dose of 0.6 mg NNC0174-0833.
Study: NCT02447263

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interventional therapy
Description: liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
Study: NCT01183871

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring of cerebral oxygenation
Description: The internal jugular vein will be cannulated using ultrasound guidance in a cephalad direction, using the Seldinger J-shaped guidewire and it will be advanced only for 2-3 cm beyond the needle insertion site to avoid vascular injury to the jugular bulb. At which point the catheter is advanced until resistance is met at the jugular bulb, usually about 15 cm. The catheter is then pulled back 0.5-1.0 cm so that the catheter does not continue to abut the roof of the jugular bulb and to minimize the cephalad vascular impact with head movement, thereby reducing the risk of vascular injury. Skull x-ray will be used to confirm placement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring of cerebral oxygenation
Description: The internal jugular vein will be cannulated using ultrasound guidance in a cephalad direction, using the Seldinger J-shaped guidewire and it will be advanced only for 2-3 cm beyond the needle insertion site to avoid vascular injury to the jugular bulb. At which point the catheter is advanced until resistance is met at the jugular bulb, usually about 15 cm. The catheter is then pulled back 0.5-1.0 cm so that the catheter does not continue to abut the roof of the jugular bulb and to minimize the cephalad vascular impact with head movement, thereby reducing the risk of vascular injury. Skull x-ray will be used to confirm placement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring of cerebral oxygenation
Description: The internal jugular vein will be cannulated using ultrasound guidance in a cephalad direction, using the Seldinger J-shaped guidewire and it will be advanced only for 2-3 cm beyond the needle insertion site to avoid vascular injury to the jugular bulb. At which point the catheter is advanced until resistance is met at the jugular bulb, usually about 15 cm. The catheter is then pulled back 0.5-1.0 cm so that the catheter does not continue to abut the roof of the jugular bulb and to minimize the cephalad vascular impact with head movement, thereby reducing the risk of vascular injury. Skull x-ray will be used to confirm placement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring of cerebral oxygenation
Description: The internal jugular vein will be cannulated using ultrasound guidance in a cephalad direction, using the Seldinger J-shaped guidewire and it will be advanced only for 2-3 cm beyond the needle insertion site to avoid vascular injury to the jugular bulb. At which point the catheter is advanced until resistance is met at the jugular bulb, usually about 15 cm. The catheter is then pulled back 0.5-1.0 cm so that the catheter does not continue to abut the roof of the jugular bulb and to minimize the cephalad vascular impact with head movement, thereby reducing the risk of vascular injury. Skull x-ray will be used to confirm placement.
Study: NCT03112213

Intervention type: DRUG
Intervention: Tocilizumab
Description: Tocilizumab (SC or IV) will be prescribed according to local clinical practice and the SPC.

Intervention type: DRUG
Intervention: NSAIDs
Description: Participants may receive NSAIDs, as prescribed by the treating physician or by self medication. Study protocol does not enforce any particular NSAID.
Study: NCT04209296

Intervention type: DRUG
Intervention: Ketamine Hydrochloride
Description: Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist has been used for general anesthesia since the 1970s, however, reports and trials by the end of the twentieth century and onward using subanesthetic doses suggested robust and rapid antidepressant and anti-suicidal effects. Ketamine is available as a 50/50 racemic mixture of enantiomers (S)-ketamine and (R)-ketamine.

Intervention type: DRUG
Intervention: Ketamine Hydrochloride
Description: Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist has been used for general anesthesia since the 1970s, however, reports and trials by the end of the twentieth century and onward using subanesthetic doses suggested robust and rapid antidepressant and anti-suicidal effects. Ketamine is available as a 50/50 racemic mixture of enantiomers (S)-ketamine and (R)-ketamine.

Intervention type: DRUG
Intervention: Ketamine Hydrochloride
Description: Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist has been used for general anesthesia since the 1970s, however, reports and trials by the end of the twentieth century and onward using subanesthetic doses suggested robust and rapid antidepressant and anti-suicidal effects. Ketamine is available as a 50/50 racemic mixture of enantiomers (S)-ketamine and (R)-ketamine.

Intervention type: DRUG
Intervention: Ketamine Hydrochloride
Description: Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist has been used for general anesthesia since the 1970s, however, reports and trials by the end of the twentieth century and onward using subanesthetic doses suggested robust and rapid antidepressant and anti-suicidal effects. Ketamine is available as a 50/50 racemic mixture of enantiomers (S)-ketamine and (R)-ketamine.
Study: NCT02273440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Theophylline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03566524

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrulline
Description: Ketosis prone diabetes patients (n=10) will be randomly assigned to receive either dietary supplement of citrulline or alanine as placebo. They will then cross over to the other supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alanine
Description: Ketosis prone diabetes patients (n=10) will be randomly assigned to receive either dietary supplement of citrulline or alanine as placebo. They will then cross over to the other supplement.
Study: NCT02765672

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Satisfaction with Life
Description: This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1
Study: NCT01783977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 vaccine
Description: DNA-HIV-PT123 4 mg/mL; administered as 1 mL IM in participant's deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 vaccine
Description: DNA-HIV-PT123 4 mg/mL; administered as 1 mL IM in participant's deltoid
Study: NCT02765672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Satisfaction with Life
Description: This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitness-to-Drive Screening Measure (FTDS)
Description: Fitness-to-Drive-Screening Measure will be completed twice, at baseline and at end of study

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitness-to-Drive Screening Measure (FTDS)
Description: Fitness-to-Drive-Screening Measure will be completed twice, at baseline and at end of study
Study: NCT02114645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal progesterone
Description: crinone gel is applied till fetal heart beat is detected

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaginal progesterone
Description: crinone gel is applied till fetal heart beat is detected
Study: NCT04361643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.
Description: Patients will receive Lenalidomide as a 5 mg capsule PO daily, days 1, 3 and 5, together with a prophylactic dose of low molecular weight heparin (LMWH) or therapeutic dose if needed due to previous comorbidity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive a placebo capsule PO daily, days 1, 3 and 5, together with a prophylactic dose of low molecular weight heparin (LMWH) or therapeutic dose if needed due to previous comorbidity.
Study: NCT02840058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological samples
Description: blood and tumor tissue samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti PD1/PDL1 treatment
Study: NCT01262300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Zoster Virus Vaccine (Zostavax)
Description: Single 0.65 mL subcutaneous injection of the live, attenuated VZV zoster vaccine (Zostavax; Merck, Whitehouse Station, NJ).
Study: NCT00704509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifeprunox
Description: 20 mg daily, encapsulated tablets, orally, 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated tablets, orally, 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: 600 mg daily, encapsulated tablets, orally, 12 months
Study: NCT02388516

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02390336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real mobilization-with-movement (MWM)
Description: For the MWM group, the investigator applied two techniques of mobilization with movement: one for flexion and one for medial rotation of the hip. With the hip in flexion, a stabilizing belt was placed on the medial side of the participant's thigh closest to the joint interline. The belt was placed around the pelvic region of the physical therapist, keeping a perpendicular direction to the participant's thigh. Maintaining a side slip, it was carried out a passive movement of 1) hip flexion (3x10) and 2) medial hip rotation (3x10) by the physiotherapist throughout painless amplitude.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham mobilization-with-movement (MWM)
Description: In the sham group, the investigators conducted a technical simulation. The positioning of the patient and the physical therapist was the same, however, no accessory mobilization was performed with the help of the belt and did not performed repeated movements of passive flexion or medial rotation.
Study: NCT02260102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temocillin
Description: Venous blood will be drawn (as per the protocol) for assay of temocillin on day 1 and day 4 of treatment. This is not part of our standard of care and is, therefore, an intervention. Patients are enrolled only if receiving temocillin as part of their normal standard of care (and the drug will be administered based on current recommendations \[no change due to enrollment in the study\]).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temocillin
Description: Venous blood will be drawn (as per the protocol) for assay of temocillin on day 1 and day 4 of treatment. This is not part of our standard of care and is, therefore, an intervention. Patients are enrolled only if receiving temocillin as part of their normal standard of care (and the drug will be administered based on current recommendations \[no change due to enrollment in the study\]).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temocillin
Description: Venous blood will be drawn (as per the protocol) for assay of temocillin on day 1 and day 4 of treatment. This is not part of our standard of care and is, therefore, an intervention. Patients are enrolled only if receiving temocillin as part of their normal standard of care (and the drug will be administered based on current recommendations \[no change due to enrollment in the study\]).
Study: NCT01863849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Fluval AB suspension for injection
Description: Single intramuscular injection with Fluval AB suspension for injection in both age groups

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Fluval AB suspension for injection
Description: Single intramuscular injection with Fluval AB suspension for injection in both age groups